Shionogi’s Pirespa Obtains MHLW Approval
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare approved Oct. 16 Shionogi's Pirespa (pirfenidone), indicated to treat idiopathic pulmonary fibrosis. Considering 51.7 percent of clinical studies patients developed solar photosensitivity, MHLW also cautions about exposure to sunlight while taking the drug. The ministry has notified physician associations about the drug's proper use. Physicians should inform patients of the possibilities of skin cancer caused by exposure to sunlight, and patients should avoid sun burn and direct exposure to ultraviolet light. (Click here for more - Japanese language
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.